TG Therapeutics/$TGTX
1D1W1MYTD1Y5YMAX
Capital at risk
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Ticker
- $TGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 399
- Headquarters
- Morrisville, United States
- Website
- www.tgtherapeutics.com
TG Therapeutics Metrics
BasicAdvanced
$8B
20.39
$2.77
1.67
-
Price and volume
Market cap
$8B
Beta
1.67
52-week high
$59.30
52-week low
$26.76
Average daily volume
1.8M
Financial strength
Current ratio
4.267
Quick ratio
3.552
Long term debt to equity
1.246
Total debt to equity
1.249
Interest coverage (TTM)
3.64%
Profitability
EBITDA (TTM)
136.451
Gross margin (TTM)
82.37%
Net profit margin (TTM)
55.22%
Operating margin (TTM)
17.05%
Effective tax rate (TTM)
-334.54%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
7.28%
Return on equity (TTM)
100.28%
Valuation
Price to earnings (TTM)
20.395
Price to revenue (TTM)
10.065
Price to book
13.73
Price to tangible book (TTM)
13.26
Price to free cash flow (TTM)
462.907
Free cash flow yield (TTM)
0.22%
Free cash flow per share (TTM)
0.122
Growth
Revenue change (TTM)
76.08%
Earnings per share change (TTM)
667.52%
3-year revenue growth (CAGR)
221.54%
10-year revenue growth (CAGR)
135.50%
3-year earnings per share growth (CAGR)
29.65%
10-year earnings per share growth (CAGR)
8.20%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
Analyst projections of the future price of TG Therapeutics stock.
Bulls say / Bears say
BRIUMVI is showing strong commercial traction: US net product revenue rose 64% year on year to $227.7 million in the second quarter. TG Therapeutics responded by raising its 2026 US BRIUMVI guidance to $890–905 million and total global revenue guidance to about $950 million. (GlobeNewswire)
The commercial business is starting to provide financial support for further development. TG Therapeutics reported second-quarter operating income of $21.7 million, held $612.3 million in cash and investments, and said projected BRIUMVI revenue should fund its current operating plan. (GlobeNewswire)
TG Therapeutics remains heavily dependent on one product. BRIUMVI generated almost all of the $240.3 million quarterly revenue, leaving the company exposed to a loss of market share, pricing or reimbursement pressure, supply problems, or weaker demand in relapsing multiple sclerosis. (Last10K)
Strong sales are not yet translating into consistently strong reported earnings. Second-quarter net income was $7.8 million, down from $28.2 million a year earlier, while the company expects $350–400 million of operating expenses plus about $100 million for subcutaneous BRIUMVI manufacturing and secondary-source start-up costs in 2026. (GlobeNewswire)
Much of the longer-term growth case still depends on unapproved programmes. The subcutaneous formulation and the simplified initiation regimen require successful trials, regulatory approval and commercial uptake, with subcutaneous Phase 3 results expected around year-end 2026 or early 2027. (BioSpace, Last10K)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
TG Therapeutics News
AllArticlesVideos
Funds containing TG Therapeutics
AllUSDEURGBP
Fund name | Fund size | $TGTX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.80% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.80% |
iShares Healthcare Innovation£DRDR | £1B | 0.80% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.43% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.43% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.